# Positioning Synapse Data (NEEDS REVIEW)

## The Problem

The pharma and biotech industry is investing heavily in AI — yet [68% of technology executives say weak data quality and governance is the primary reason those investments fail](https://www.zs.com/insights/scaling-ai-in-pharma-cdio-2026), not the algorithms. The bottleneck is upstream: data that is fragmented, poorly governed, and modelled without scientific literacy that no AI system can reliably consume. The algorithms exist. The pipelines do not.

The root cause is structural. Biomedical data spans clinical notes, electronic health records, genetic sequencing, imaging, and regulatory submissions — each governed by a completely different domain model. A technically correct pipeline built without deep scientific understanding produces biologically meaningless results. The regulatory exposure is real: data integrity violations appear in [60–80% of FDA GMP warning letters](https://www.astrixinc.com/blog/trends-in-fda-data-integrity-483s-and-warning-letters-for-pharmaceutical-companies/), the single most cited compliance failure in the industry. And the cost of getting the science wrong is concrete: an estimated [$28 billion per year is lost to irreproducible preclinical research](https://journals.plos.org/plosbiology/article?id=10.1371/journal.pbio.1002165), in part due to data analysis and reporting failures.

This plays out differently depending on organization size, but the underlying gap is the same — people who understand both the biology and the engineering are genuinely scarce. [49% of pharma professionals identify the skills gap as the single biggest barrier to digital transformation.](https://intuitionlabs.ai/articles/pharma-ai-skills-gap) Large pharma accumulates deep expertise in siloed departments — Discovery, Translational Science, Clinical, RWE — but [integrating data across those silos is where value is created and where it is currently lost.](https://pmc.ncbi.nlm.nih.gov/articles/PMC8025897/) Smaller biotech cannot staff all of those competencies at once. Both are compounded by a constraint no internal investment fully solves: patient-level data cannot legally be centralized across institutions under GDPR and HIPAA, so population-level evidence requires federated architectures that general data engineering firms are not designed to build.

## Vision

A life science industry where biomedical data connects as fluently as synapses in the nervous system.

## Mission

Biomedical data pipelines fail not because the engineering is wrong, but because the science is. Synapse Data's mission is to close that gap: building AI-ready biomedical data infrastructure where scientific reasoning is present at every level — in the data models, the pipelines, the clinical standards, and the governance — not as advisory input handed to engineers, but as the capability doing the work. Executed on Databricks, a [data platform widely adopted in pharma](https://datameshlearning.com/blog/recap-data-mesh-days-for-life-sciences/) for complex, high-volume analytical workloads.

## Why Synapse Data

The rarest thing in biomedical data is not tooling or budget — it is a person who can reason through a clinical data modelling decision with a biostatistician, implement the resulting pipeline correctly, and defend its regulatory traceability to a compliance team. That combination almost never exists in a single role. The result is what the problem statement describes: technically correct pipelines that encode wrong domain assumptions, AI systems trained on data that answers the wrong questions, and [$28 billion per year lost to research that cannot be reproduced](https://journals.plos.org/plosbiology/article?id=10.1371/journal.pbio.1002165).

Synapse Data is built around making that capability available. A founder with a PhD in Life Sciences (Paris-Saclay), a master's in Biophysics (KU Leuven), and a postgraduate in Applied AI (EhB), combined with hands-on data engineering and product ownership in industry, means scientific reasoning is present at implementation level — not in an advisory layer above the engineers. Concretely: this is the difference between a data model that happens to store OMOP fields and one designed by someone who understands why a given clinical concept maps the way it does. Or between a federated pipeline spec and one that will actually hold under the data governance constraints of a multi-site research consortium.

## Competitive Landscape

| | Who | The gap they leave |
|---|---|---|
| **Enterprise platforms** | [Palantir Foundry](https://www.palantir.com/offerings/life-sciences/), IQVIA | Enterprise-only pricing and implementation burden; out of reach for most biotechs and mid-size pharma |
| **Large consultancies** | [Thoughtworks](https://www.thoughtworks.com/en-us/insights/blog/data-strategy/the-state-of-data-mesh-in-2026-from-hype-to-hard-won-maturity) *(ran the [Roche data mesh](https://datameshlearning.com/blog/recap-data-mesh-days-for-life-sciences/) — the reference implementation for pharma)* | Sound methodology, but large-consultancy overhead and cost; unreachable for smaller clients |
| **Mid-market life sciences IT** | [Agilisium](https://www.agilisium.com/about) *([Everest Group leader, life sciences mid-market](https://industries.agilisium.com/newsrooms/agilisium-recognized-as-a-leader-in-everest-group-life-sciences-digital-services-for-mid-market-enterprises-peak-matrix-report-2024))* | Genuine domain knowledge and strong Databricks delivery — but no visible OMOP/CDM capability; scientific depth sits at VP advisory level while engineers execute; model requires large embedded enterprise engagements |
| **Data platforms** | [Lifebit](https://lifebit.ai), DNAnexus, Snowflake Health Data Cloud | Purpose-built platforms — strong at what they do, but require data handover into their ecosystem; not consulting partners who build on your infrastructure and leave you owning the result |

**The position Synapse Data occupies**: None of the above solve the core problem the problem statement names — scientifically mismodelled data built by teams where the domain knowledge and the engineering capability are in different people. Agilisium comes closest but leaves the OMOP gap, keeps science advisory, and cannot right-size for smaller clients. Synapse Data is the answer when the bottleneck is not capacity or methodology, but the specific combination of scientific depth and engineering execution in one engagement.

## Services

- **Data products** with quality enforcement, refresh patterns, and lineage — built to modern engineering best practices
- **Clinical standards integration** (OMOP, CDM) so data products speak the language of clinical data teams from day one
- **GenAI pipelines** for structured data extraction, designed for regulated environments
- **Data governance** — audit trails, lineage tracking, and access control designed for clinical research contexts
- **Data models** that reflect biological and clinical reality, not just storage convenience

## Go-to-Market

Synapse Data partners with established intermediary consulting agencies that hold master service agreements with large pharma clients. This positions Synapse Data as a scientific domain specialist within larger engagements, without requiring the firm to navigate enterprise procurement directly. Direct engagements target mid-size pharma, Series A/B biotechs, and academic spin-outs where the founder's scientific background is an immediate credibility signal.

## Data Products

Beyond consulting, Synapse Data is building a line of open-source data products distributed via the [Databricks Marketplace](https://www.databricks.com/product/marketplace) and API access — reference implementations of the data infrastructure problems pharma faces most often: OMOP-standardized disease and genetic datasets, FAIR-compliant data product templates, and quality-enforced reference data for common biomedical entities.

**Who this is for**: Small biotechs and academic groups who need production-quality biological data infrastructure but cannot engage a consulting firm. This segment is structurally underserved — too small for enterprise platform vendors, too specialised for generic cloud providers, and unable to staff the dual scientific-engineering competency internally.

**The model**: Core implementations are open-source. Databricks Marketplace listings provide installable, documented starting points. API access enables programmatic consumption of reference datasets. Non-commercial use is free.

**Why this does not conflict with the consulting business**: The product is the foundation; the consulting is what makes that foundation production-ready, scientifically appropriate for a specific problem, and regulatorily defensible in a specific regulated environment. Consulting clients are not paying for templates — they are paying for the scientific domain reasoning that determines whether a given design is right for their context. This model is well-established in pharma data tooling: the [OHDSI community](https://www.ohdsi.org/) built the world's largest network of observational health databases on open-source tooling, with implementation and consulting support sitting entirely on top. The open product also functions as a credibility signal and lead-generation channel: the organisations that grow beyond it become consulting clients.

## Building Towards

**AI-ready accelerators**: Each consulting engagement contributes to a growing library of reusable assets built for a specific purpose — compressing time-to-AI-readiness rather than rebuilding the same foundations repeatedly. These include OMOP-ready data product templates, data quality frameworks calibrated to genomic and clinical data, GenAI extraction pipelines for biomedical literature, and data mesh scaffolding for Databricks Unity Catalog. The [evidence that AI projects fail at the data layer, not the model layer](https://www.zs.com/insights/scaling-ai-in-pharma-cdio-2026), makes these assets commercially valuable beyond individual engagements.

**Federated architecture frameworks**: The legal constraint that patient-level data cannot be centralized across institutions under GDPR and HIPAA is not going away. Synapse Data is building reusable patterns for federated data architectures — designs that allow computation to run at the data source, with only aggregated or anonymized results shared centrally. [This is increasingly required for multi-site research and cross-institutional RWE programs](https://www.frontiersin.org/journals/drug-safety-and-regulation/articles/10.3389/fdsfr.2025.1579922/full) and represents a specialisation general data engineering firms are not built for.

**GxP-readiness**: The ability to deliver pipelines that clients can validate under 21 CFR Part 11 and ALCOA+ requirements is a meaningful differentiator in regulated pharma contexts. Synapse Data is developing this capability through current project work, with the goal of offering validated pipeline frameworks as a defined service — directly addressing the data integrity failures that appear in [60–80% of FDA GMP warning letters](https://www.astrixinc.com/blog/trends-in-fda-data-integrity-483s-and-warning-letters-for-pharmaceutical-companies/).
